Placental Mesenchymal Stem Cells

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Placental Mesenchymal Stem Cells
DrugBank Accession Number
DB15730
Background

The placenta serves many purposes, with one of the many being a bank of mesenchymal stem cells (MSCs). It can be obtained relatively easily as medical waste from which MSCs can be non-invasively extracted and without the ethical issues that come with embryonic stem cells. The placental MSCs (pMSCs) are obtained from either the fetal side, which hold chorionic plate-derived MSCs, or the maternal side, which contributes decidual parietalis-dreived MSCs. Although pMSCs have multi-lineage differentiation potential, the fetal-side pMSCs have greater expansion capacity, proliferation and differentiation potential than maternal-side pMSCs. It was also found that fetal-side pMSCs express different surface markers.

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
  • Placental mesenchymal stromal cells
  • PLX-PAD
External IDs
  • Placental Mesenchymal Stem Cells

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action

All pMSCs contain therapeutic potential and have been used in medical treatment already as they are an ideal candidate for allogeneic transplantation due to their immunomodulatory properties and low immunogenicity. MSCs secrete growth factors and cytokines during angiogenesis, anti-fibrotic processes, chemotaxis, hematopoiesis induction, immunomodulation, and inhibition of apoptosis, with different levels of secretion between fetal- vs. maternal-side pMSCs. Fetal-side pMSCs secrete a higher level of HGF and VCAM-1 and hold potential in angiogenic therapy, while maternal-side pMSCs have the potential for treatment of critical limb ischemia as they secrete VEGF and Ang-1.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Wu M, Zhang R, Zou Q, Chen Y, Zhou M, Li X, Ran R, Chen Q: Comparison of the Biological Characteristics of Mesenchymal Stem Cells Derived from the Human Placenta and Umbilical Cord. Sci Rep. 2018 Mar 22;8(1):5014. doi: 10.1038/s41598-018-23396-1. [Article]
  2. Papait A, Vertua E, Magatti M, Ceccariglia S, De Munari S, Silini AR, Sheleg M, Ofir R, Parolini O: Mesenchymal Stromal Cells from Fetal and Maternal Placenta Possess Key Similarities and Differences: Potential Implications for Their Applications in Regenerative Medicine. Cells. 2020 Jan 6;9(1). pii: cells9010127. doi: 10.3390/cells9010127. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentCritical Limb Ischemia (CLI)1
3RecruitingTreatmentHip Fracture1
2CompletedTreatmentIntermittent Claudication / Peripheral Artery Disease (PAD)1
2RecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS) / Coronavirus Disease 2019 (COVID‑19) / COVID2
1CompletedTreatmentCritical Limb Ischemia (CLI) / Peripheral Artery Disease (PAD) / Peripheral Vascular Disease Patient2
1TerminatedTreatmentSymptomatic pulmonary arterial hypertension (PAH)1
1, 2CompletedTreatmentMuscle Injuries / Total Hip Arthroplasty (THA)1
1, 2RecruitingTreatmentMyelomeningocele1
Not AvailableAvailableNot AvailableCritical Limb Ischemia (CLI)2
Not AvailableRecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS) / Coronavirus Disease 2019 (COVID‑19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 19:12 / Updated on August 13, 2020 07:02